Latest Ergothioneine Stories

SHERWOOD, Ore., April 2, 2013 /PRNewswire/ -- Entia Biosciences (OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has now received three Patent Notices of Allowance covering the use of Ergothioneine and its genetic transporter in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Notices from the United States Patent and Trademark Office and the Israel Patent Office were...

SHERWOOD, Ore., Jan. 7, 2013 /PRNewswire/ -- Entia Biosciences (OTCBB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, announced today that it has filed a PCT patent covering the use of Ergothioneine and/or Vitamin D2 to improve the growth and health of hair, skin and nails. The scientific knowledge underpinning this application claims priority to a provisional use patent filed on December 29, 2011 that addresses naturally and...

SHERWOOD, Ore., Dec. 17, 2012 /PRNewswire/ -- Entia Biosciences (OTCBB: ERGO), a food science biotechnology company and emerging leader in the fields of Nutrigenomics and Targeted Nutrition, has received a Patent Notice of Allowance from the Canadian Intellectual Property Office covering the use of Ergothioneine and its genetic transporter (SLC22A4) in the treatment of a wide variety of diseases, including those affecting the immune and central nervous systems. Ergothioneine is a...

SHERWOOD, Ore., June 13, 2012 /PRNewswire/ -- Entia Biosciences, Inc. (OTCBB: ERGO) (ENTIA) today announced that it has received a patent from the Nation of Canada covering the "Use of Ergothioneine as a Preservative in Foods and Beverages." The new patent No. 2,680,223 expires on March 7, 2028 and has also been filed with the United States Patent Office and the European Union. The food and beverage preservation patent is the first of the Company's many patent applications to issue...

Skincare Market Inc. is proud to introduce such an advanced product for the lowest price possible. This new product reduces wrinkles and blemishes on the face and neck by simply applying it overnight. Los Angeles, CA (PRWEB) March 15, 2012 Skincare Market Inc. releases a new product called the Kinerase Pro+ Therapy MD Advanced Ultra Rich Night Repair that moisturizes and tightens the facial skin overnight. With peptides combining with cleansing antioxidants, this product helps the skin...

BEVERLY HILLS, Calif., July 11, 2011 /PRNewswire/ -- OXIS International, Inc. (OTC/BB: OXIS.OB; Euronext Paris: OXI) today announced that it has formed a joint venture with John E. Repine, M.D. to develop ergothioneine as a potential intervention to treat and prevent Acute Lung Injury (ALI), including the most severe form of ALI known as Acute Respiratory Distress Syndrome (ARDS). The joint venture has the rights to patent-pending technology created by Dr. Repine covering the use of...

BEVERLY HILLS, Calif., June 20, 2011 /PRNewswire/ -- OXIS International, Inc. (OTC Bulletin Board: OXIS; Euronext Paris: OXI) announces that online registration is now open for the "First International Congress on Ergothioneine, Antioxidants & Age Management Medicine" being held Friday, July 15 through Sunday, July 17 at the DeNeve Auditorium on the campus of the University of California Los Angeles. Participants can register at www.ergocongress.com. The website also contains the...

BEVERLY HILLS, Calif., March 18, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) will be conducting a conference call and webcast with investors on Tuesday, March 22, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). During the call Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will review significant business developments, discuss the Company's growth strategy, and take questions from call attendees. Individuals interested in...

BEVERLY HILLS, Calif., March 10, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) today announced that it will hold a conference call with investors on Tuesday, March 22, 2011 at 11:00 a.m. Eastern (8:00 a.m. Pacific). During the call Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will review significant business developments, discuss the Company's growth strategy, and take questions from call attendees. Individuals interested...

BEVERLY HILLS, Calif., Feb. 14, 2011 /PRNewswire/ -- OXIS International, Inc., (OTC Bulletin Board: OXIS; Paris: OXI) today announced that Anthony Cataldo, Chief Executive Officer, and Bernie Landes, President, will present to investors as part of the Lippert/Heilshorn & Associates Life Sciences & Medical Technologies On-Line Forum on Thursday, February 17, 2011 at 12:30 p.m. Eastern (9:30 a.m. Pacific). A webcast of the presentation will be accessible online on at the PrecisionIR...